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Abstract
Background: The optimal timing of salvage radiotherapy for biochemical recurrence after radical prostatectomy is
controversial. In particular, the prognostic significance of salvage radiotherapy delivered before a current definition
of biochemical recurrence, i.e. ultra-early salvage radiotherapy, is unclear.
Methods: We reviewed 76 patients with pT2-3N0M0 prostate cancer who underwent salvage radiotherapy for post-
prostatectomy biochemical recurrence at the following three timings: ultra-early salvage radiotherapy (n = 20)
delivered before meeting a current definition of biochemical recurrence (two consecutive prostate-specific antigen
[PSA] values ≥0.2 ng/mL); early salvage radiotherapy (n = 40) delivered after meeting the definition but before PSA
reached 0.5 ng/mL; and delayed salvage radiotherapy (n = 16) delivered after PSA reached 0.5 ng/mL. The primary
endpoint was failure of salvage radiotherapy, defined as a PSA value ≥0.2 ng/mL. The log-rank test and Cox
proportional hazards model were used for univariate and multivariate analyses, respectively.
Results: During the follow-up period (median: 70 months), four of 20 (20 %), nine of 40 (23 %) and seven of 16
(44 %) patients failed biochemically in the ultra-early, early and delayed salvage radiotherapy groups, respectively.
On univariate analyses, the outcome of delayed salvage radiotherapy was worse than the others, while there was
no significant difference between ultra-early and early groups. Multivariate analysis demonstrated the presence of
Gleason pattern 5, perineural invasion and delayed salvage radiotherapy as independent predictors of poorer
survival.
Conclusions: No survival benefit of ultra-early salvage radiotherapy was demonstrated, whereas delayed salvage
radiotherapy was associated with worse outcome as reported in previous studies. Our results may support the
current recommendations that salvage radiotherapy should be undertaken after two consecutive PSA values ≥0.
2 ng/mL and before reaching 0.5 ng/mL.
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Background
Approximately 25–35 % of patients develop biochemical
recurrence (BCR) after radical prostatectomy (RP) for
clinically localized prostate cancer (PC) [1, 2]. Although
salvage radiotherapy (SRT) is a standard treatment op-
tion for post-RP BCR [3–5], there is currently no con-
sensus regarding its optimal timing. There are several
commonly used definitions of BCR; most involve single
or multiple prostate-specific antigen (PSA) values of at
least ≥0.2 [6], including the current official definition in
Japan of two consecutive PSA values ≥0.2 ng/mL [7]. To
the best of our knowledge, the value of SRT delivered
before meeting these definitions has not been investigated
to date. We previously reported that salvage androgen
deprivation therapy (ADT) administered before meeting
the Japanese definition, referred to as “ultra-early sal-
vage ADT”, achieved a better oncological outcome than
ADT administered after patients met the definition in
pT2-4 N0 PC [8].
On the other hand, several recent studies have sug-
gested that SRT should be started before PSA levels
reach 0.5 ng/mL [9–13]. Notably, Briganti et al. dem-
onstrated that early SRT (eSRT; given at pre-radiation
PSA ≤0.5 ng/mL) achieved an oncological outcome
equivalent to adjuvant radiotherapy in patients with
pT3N0 PC [10].
In this context, the present study aimed to investigate
the benefit of SRT given before patients meet a currently
used definition [7] (i.e. ultra-early SRT; ueSRT), by com-
paring the outcomes of patients treated with SRT at
different timings after RP.
Methods
Patients
This retrospective analysis was approved by the internal
institutional review board of Graduate School of Medi-
cine and Faculty of Medicine, The University of Tokyo
(approval number: 3124). We reviewed 96 patients who
underwent SRT after RP at our institution between 2006
and 2014. Of them, 19 patients who received ADT (neo-
adjuvant and/or adjuvant: 13; salvage: 6) prior to SRT
and a patient who underwent SRT for pN1 disease were
excluded. Finally, we retrospectively reviewed 76 patients
with pT2-3N0M0 PC who underwent SRT after RP at
our institution during this period. Of the 76 patients, 20
(26 %) received ueSRT for increasing PSA but before
they met a current definition of BCR (two consecutive
PSA values ≥0.2 ng/mL [7]); 40 (53 %) received eSRT
after meeting the definition but before PSA reached
0.5 ng/mL; and 16 (21 %) received delayed SRT (dSRT)
after PSA reached 0.5 ng/mL. All 20 patients in the
ueSRT group had at least one detectable PSA value, al-
though they did not meet the above definition of BCR:
In more details, 18 of 20 (90 %) patients started SRT
before PSA values reached 0.2 ng/mL; and the remaining
2 (10 %) did it over only a single PSA value of 0.2 ng/mL.
PSA doubling time was calculated in patients who
had at least three PSA measurements after BCR but
before initiating SRT, using all PSA measurements.
The calculation assumed first-order kinetics, dividing
the natural logarithm of 2 by the slope of the log
PSA vs time of PSA measurements for each patient
(in months) [14].
Treatments
The most common surgical procedure of open RP with
bilateral obturator lymph node dissection was performed
in 59 (78 %) patients. Laparoscopic RP and robot-
assisted laparoscopic RP were performed in six (8 %)
and 11 (14 %) patients, respectively.
The standard technique for SRT was 3-dimensional
conformal radiation therapy (3DCRT) in 61 (80 %) pa-
tients, while 15 (20 %) patients were treated with
intensity-modulated radiotherapy (IMRT) to cover the
prostate bed with reference to preoperative computed
tomography and/or magnetic resonance imaging (Table 1).
The most common delivered dose was 66 Gy, though a
few (6 of 76 [8 %]) patients received 70 Gy by IMRT with
a simultaneous integrated boost to suspicious recurrent
lesions detected by multi-parametric magnetic resonance
imaging in addition to 66 Gy to the prostate bed, as per
our ongoing prospective study (UMIN000009823: Dy-
namic contrast-enhanced magnetic resonance imaging
study for biochemical failures after radical prostatectomy).
All SRT regimens were given in 1.8–2.0-Gy daily fractions.
For pre-radiation studies, computed tomography was
used in most patients, whereas six (8 %) who partici-
pated in the prospective study mentioned above under-
went 3-tesla dynamic contrast enhanced magnetic
resonance imaging.
Endpoints and statistical analysis
The primary endpoint was failure of SRT, defined as a
PSA value ≥0.2 ng/mL after PSA nadir following SRT
[9]. Secondary endpoints were clinical metastasis and
cancer-specific mortality. Associations of various clinico-
pathological factors, including timing of SRT, with
failure-free survival were assessed. Survival time was de-
fined as the time (months) between RP and failure of
SRT or last follow-up [10]. The log-rank test and Cox
proportional hazards model were used for univariate and
multivariate analyses, respectively. All statistical analyses
were performed using JMP Pro version 11.0.0 (SAS
Institute, Cary, NC, USA). A value of P < 0.05 was con-
sidered significant. Follow-up information was obtained
as of August 2015.
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Results
The patient characteristics of the whole population (n = 76)
and according to the timing of SRT are summarized
in Table 1. During the follow-up period (median:
70 months; interquartile range: 48–95 months), four of 20
(20 %), nine of 40 (23 %) and seven of 16 (44 %) patients
developed failure of SRT in the ueSRT, eSRT and dSRT
groups, respectively. The outcome of dSRT was signifi-
cantly worse than the others (log-rank test: P = 0.0424
for ueSRT; P = 0.0333 for eSRT), while there was no sig-
nificant difference between ueSRT and eSRT (P = 0.6171,
Fig. 1). Furthermore, there was a stronger outcome
difference when comparing ueSRT + eSRT and dSRT
(P = 0.0108, Fig. 2), whereas no significant difference
was observed when comparing ueSRT and eSRT + dSRT
(P = 0.2991, Fig. 3).
Table 1 Patient characteristics
Parameter Total (n = 76) ueSRT (n = 20) eSRT (n = 40) dSRT (n = 16) P
Age at surgery, years, median (IQR) 65 (61–69) 68 (61–72) 65 (61–69) 64 (57–67) 0.0574a
Initial PSA, ng/mL, median (IQR) 8.7 (6.4–12.6) 9.2 (6.9–12.6) 8.4 (5.9–13.0) 9.3 (7.2–12.9) 0.6684a
Pathological T stage, no. (%):
T2 37 (49) 9 (45) 21 (53) 7 (44) 0.0834b
T3a 35 (46) 10 (50) 19 (48) 6 (38)
T3b 4 (5) 1 (5) 0 (0) 3 (19)
Pathological GS, no. (%):
≤6 12 (16) 3 (15) 6 (15) 3 (19) 0.1533b
7 49 (64) 16 (80) 26 (65) 7 (44)
≥8 15 (20) 1 (5) 8 (20) 6 (38)
Gleason pattern 5 (including tertiary 5) 27 (36) 5 (25) 14 (35) 8 (50) 0.2959b
Extraprostatic extension, no. (%) 37 (49) 10 (50) 18 (45) 9 (56) 0.7416b
Lymphovascular invasion, no. (%) 21 (28) 3 (15) 10 (25) 8 (50) 0.0568b
Positive surgical margin, no. (%) 57 (75) 17 (85) 28 (70) 12 (75) 0.4493b
Seminal vesicle invasion, no. (%) 4 (5) 1 (5) 0 (0) 3 (19) 0.0178*b
Perineural invasion, no. (%) 58 (76) 17 (85) 28 (70) 13 (81) 0.3805b
SRT technique, no. (%):
3DCRT 61 (80) 19 (95) 27 (68) 15 (94) 0.0130*b
IMRT 15 (20) 1 (5) 13 (33) 1 (6)
Total dose, no. (%):
60–65 Gy 10 (13) 3 (15) 5 (13) 2 (13) 0.9646b
66 Gy 60 (79) 16 (80) 31 (78) 13 (81)
70 Gy 6 (8) 1 (5) 4 (10) 1 (6)
Concomitant ADT, no. (%) 12 (16) 5 (25) 2 (5) 5 (31) 0.0218*b
PSA doubling time, months, median (IQR) 8.4 (4.6–20.1) –† 12.7 (6.2–25.1) 5.9 (3.5–14.3) –
Median follow-up, months (IQR) 70 (48–95) 74 (57–99) 73 (43–83) 58 (41–99) 0.5386a
SRT salvage radiotherapy, ueSRT ultra-early salvage radiotherapy, eSRT early salvage radiotherapy, dSRT delayed salvage radiotherapy, IQR interquartile range, PSA
prostate-specific antigen, GS Gleason score, 3DCRT 3-dimensional conformal radiation therapy, IMRT intensity-modulated radiotherapy, ADT androgen
deprivation therapy
*Statistically significant; aone-way ANOVA; bPearson’s χ2 test
†In the ueSRT group, PSA doubling time was only calculable in two patients (3.9 and 5.6 months)
Fig. 1 Kaplan–Meier curves depicting failure-free survival according
to three timings of SRT (log-rank test: P = 0.0364)
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Univariate analysis revealed that the presence of
Gleason pattern 5 (including tertiary pattern 5), lympho-
vascular invasion, perineural invasion, timing of SRT
(ueSRT vs eSRT vs dSRT; and ueSRT + eSRT vs dSRT)
and PSA doubling time <6 months were associated with
poorer failure-free survival (Table 2). Of the two covari-
ates regarding the timing of SRT, we only included
“ueSRT + eSRT and dSRT” (a stronger one) but not
“ueSRT vs eSRT vs dSRT” (a weaker one) in the subse-
quent multivariate model, because these factors should
be closely-correlated and would therefore cancel out
each other’s statistical significance (i.e. multicollinearity).
PSA doubling time was also excluded from the model,
since it was only calculable in 51 (67 %) patients.
Accordingly, multivariate analysis identified the presence
of Gleason pattern 5, perineural invasion and dSRT
(reference: ueSRT + eSRT) as independent predictors of
failure of SRT (Table 2).
Concerning the treatment modality, although univari-
ate analysis did not demonstrate a significant difference
between 3DCRT vs IMRT, IMRT exhibited a non-
significant trend for better failure-free survival than
3DCRT: 2 of 15 (13 %) patients who underwent IMRT
failed biochemically, whereas 18 of 61 (30 %) who re-
ceived 3DCRT did.
With regard to the secondary endpoints, two pa-
tients (3 %) in the dSRT group developed clinical me-
tastases: One developed a solitary metastasis to a right
iliac lymph node but has achieved undetectable PSA
with subsequent salvage ADT; and another developed
multiple metastases to bone and para-aortic lymph
nodes and finally died of PC. No other patient than
the latter one died from any cause during the follow-
up period.
Discussion
The present study compared outcomes of different
timings of SRT for post-RP BCR, especially focusing
on the prognostic significance of ueSRT. During the
follow-up period (median: 70 months), four of 20
(20 %), nine of 40 (23 %) and seven of 16 (44 %) pa-
tients failed biochemically in the ueSRT, eSRT and
dSRT groups. No survival benefit of ueSRT compared
to eSRT was demonstrated in the study, whereas
dSRT was associated with worse prognosis as previ-
ously reported. These results thus support the current
recommendations that SRT should be performed after
two consecutive PSA values ≥0.2 ng/mL and before
reaching 0.5 ng/mL [9–13].
To the best of our knowledge, no previous study has
investigated the effects of SRT given before patients
meet the current definition of BCR. Although we previ-
ously demonstrated the benefit of ultra-early salvage
ADT for post-RP BCR in pT2-4 N0 patients [8], this re-
sult was not reproducible for ueSRT. This difference
may be attributable to the difference between systemic
ADT and local radiation therapies, though the reason
currently remains unclear.
Several studies have associated SRT given at a pre-
radiation PSA ≤0.5 ng/mL with better outcomes [9–13],
although current guidelines only recommend a pre-
radiation PSA <1.0 ng/mL [3, 4]. For example, Briganti
et al. demonstrated that eSRT given before PSA reached
0.5 ng/mL achieved an equivalent oncological outcome
to adjuvant radiotherapy in patients with pT3N0 PC, as
stated above [10]. Several clinical trials comparing the
outcomes of adjuvant radiotherapy and eSRT are now
underway to clarify this issue (RAVES; EORTC 22043-
30041; GETUG-17) [11, 15].
Fig. 2 Kaplan–Meier curves depicting failure-free survival of ueSRT +
eSRT vs dSRT (log-rank test: P = 0.0108)
Fig. 3 Kaplan–Meier curves depicting failure-free survival of ueSRT vs
eSRT + dSRT (log-rank test: P = 0.2991)
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Pathological Gleason pattern 5, including tertiary pat-
tern 5, was an independent predictor of failure-free sur-
vival in this study. Some previous studies also reported
that Gleason pattern 5 was a strong prognostic factor in
patients undergoing salvage treatments (SRT and/or
ADT) for post-RP BCR [16, 17]. Gleason pattern 5 may
thus be a more critical marker than conventional Glea-
son grading system in this setting.
Perineural invasion was also identified as an independ-
ent predictor of failure-free survival. Several studies have
reported perineural invasion as a significant prognostic
factor in the setting of SRT for post-RP BCR [18–21].
Our results are in complete accord with these previous
studies.
With regard to the treatment modality, although uni-
variate analysis did not demonstrate a significant differ-
ence between 3DCRT vs IMRT, those who underwent
IMRT (n = 15) had a relatively favorable outcome: Only
2 of 15 (13 %) patients failed biochemically. As new
technologies such as IMRT and/or image-guided radio-
therapy have improved outcomes of external beam
radiotherapy [22], its evaluations should be updated
often.
Our study had several limitations. The ueSRT group
may have included patients without evidence of BCR,
which may have resulted in overestimation of the out-
comes of ueSRT. Other limitations were its retrospective
design, small sample size, selection bias and lead-time
bias. Randomized prospective studies with longer follow-
up periods are thus needed to confirm these preliminary
results.
Conclusions
No survival benefit of ueSRT was shown in patients
with post-RP BCR, whereas dSRT was associated with
poorer outcome as reported in previous studies.
These results may validate the current recommenda-
tions that SRT should be performed after two con-
secutive PSA values ≥0.2 ng/mL and before reaching
0.5 ng/mL.
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Table 2 Univariate and multivariate analyses of clinicopathological factors for failure-free survival
Parameter Cutoff Univariate Multivariate
P HR (95 % CI) P
Age ≥65 years vs <65 years† 0.2151
Initial PSA ≥20 ng/mL vs <20 ng/mL 0.9923
Pathological T stage ≥T3 vs≤ T2 0.5521
Pathological GS ≥8 vs ≤7 0.0558
Gleason pattern 5 Yes vs no 0.0004* 4.166 (1.351 to 12.76) 0.0133*
Extraprostatic extension Yes vs no 0.4370
Lymphovascular invasion Yes vs no 0.0101* 1.005 (0.323 to 3.130) 0.9935
Positive surgical margin Yes vs no 0.2967
Seminal vesicle invasion Yes vs no 0.1506
Perineural invasion Yes vs no 0.0157* 5.876 (1.139 to 107.5) 0.0316*
Timing of SRT ueSRT vs eSRT vs dSRT 0.0364* – –‡
ueSRT + eSRT vs dSRT 0.0108* 3.117 (1.141 to 7.880) 0.0280*
ueSRT vs eSRT + dSRT 0.2991
SRT technique 3DCRT vs IMRT 0.4964
Total dose ≥66 Gy vs <66 Gy 0.6278
Concomitant ADT Yes vs no 0.3118
PSA doubling time ≥6 months vs <6 months 0.0071* – –‡
HR hazard ratio, CI confidence interval, PSA prostate-specific antigen, GS Gleason score, SRT salvage radiotherapy, ueSRT ultra-early salvage radiotherapy, eSRT early
salvage radiotherapy, dSRT delayed salvage radiotherapy, 3DCRT 3-dimensional conformal radiation therapy, IMRT intensity-modulated radiotherapy, ADT androgen
deprivation therapy
†median; *statistically significant; ‡these covariates were excluded from the multivariate analysis (see text)
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